Neff Thomas B Form 4 June 22, 2018

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box

if no longer subject to Section 16. Form 4 or

Form 5

1(b).

(Last)

obligations

may continue.

See Instruction

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person * Neff Thomas B

> (First) (Middle)

C/O FIBROGEN, INC., 409 ILLINOIS ST.

06/20/2018

Stock

2. Issuer Name and Ticker or Trading Symbol

FIBROGEN INC [FGEN] 3. Date of Earliest Transaction

(Month/Day/Year) 06/20/2018

(Street) 4. If Amendment, Date Original

Filed(Month/Day/Year)

OMB APPROVAL

OMB 3235-0287 Number:

January 31, Expires: 2005

Estimated average burden hours per

response... 0.5

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

_X__ Director 10% Owner X_ Officer (give title Other (specify below) below)

Chief Executive Officer

6. Individual or Joint/Group Filing(Check

Applicable Line)

X Form filed by One Reporting Person Form filed by More than One Reporting

SAN FRANCISCO, CA 94158 Person (City) (State) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1. Title of 2. Transaction Date 2A. Deemed 3. 4. Securities Acquired 5. Amount of 7. Nature of Security (Month/Day/Year) Execution Date, if Transaction(A) or Disposed of (D) Securities Ownership Indirect (Instr. 3) Code (Instr. 3, 4 and 5) Beneficially Form: Beneficial (Month/Day/Year) Owned Direct (D) Ownership (Instr. 8) Following or Indirect (Instr. 4) Reported (A) Transaction(s) (Instr. 4) (Instr. 3 and 4) Code V Amount (D) Price Common 06/20/2018 M 10,320 A \$ 3.6 2,856,353 D Stock \$ Common 7,701 S 06/20/2018 D 63.31 2,848,652 D Stock (1) (2) \$ Common 11,199 06/20/2018 S D D 63.79 2,837,453 (1) Stock (3) \$ Common By Family

798 (1)

D

63.55

(4)

108,684

I

S

Partnership

Edgar Filing: Neff Thomas B - Form 4

Common Stock	06/20/2018	S	120 (1)	D	\$ 63.97 (5)	108,564	I	By Family Partnership
Common Stock	06/21/2018	M	10,320	A	\$ 3.6	2,847,773	D	
Common Stock	06/21/2018	S	15,172 (1)	D	\$ 63.54 (6)	2,832,601	D	
Common Stock	06/21/2018	S	3,728 (1)	D	\$ 64.08 (7)	2,828,873	D	
Common Stock	06/21/2018	S	918 (1)	D	\$ 63.6 (8)	107,646	I	By Family Partnership
Common Stock						19,500	I	By Spouse
Common Stock						60,946	I	See footnote (9)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	\$ 3.6	06/20/2018		M		10,320	(10)	03/11/2019	Common Stock	10,320
Stock Option (Right to Buy)	\$ 3.6	06/21/2018		M		10,320	(10)	03/11/2019	Common Stock	10,320

Reporting Owners

Reporting Owner Name / Address Relationships

Director 10% Owner Officer Other

Neff Thomas B

C/O FIBROGEN, INC.
409 ILLINOIS ST.

X Chief Executive Officer

SAN FRANCISCO, CA 94158

Signatures

/s/ Dorothy Pacini, Attorney-in-fact

06/22/2018

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Shares sold pursuant to a 10b5-1 plan.
- (2) The shares were sold at prices ranging from \$62.55 to \$63.525. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- (3) The shares were sold at prices ranging from \$63.55 to \$64.25. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- (4) The shares were sold at prices ranging from \$62.90 to \$63.85. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- (5) The shares were sold at prices ranging from \$63.95 to \$63.975. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- (6) The shares were sold at prices ranging from \$63.10 to \$63.975. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- (7) The shares were sold at prices ranging from \$64.00 to \$64.225. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- (8) The shares were sold at prices ranging from \$63.20 to \$63.975. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- (9) The shares are held by BioGrowth Partners, LP. The reporting person is the sole general partner of BioGrowth Partners, LP and has sole voting and dispositive power over the shares held by BioGrowth Partners, LP.
- (10) Fully vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 3